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L E T T E R TO THE E D I T OR
A totally new system is needed for drug research and
development
In response to my paper,1 where I call for abolishment of
patents and for drug research and development as a public
enterprise, Raj asserts that there is an increase in novel
drug discoveries. The fact is that even the drug industry
laments that drug innovation has dried out, which is why
they buy start-up companies. Big Pharma doesn’t invest in
innovative research, as it is far more profitable to have cre-
ative marketing and legal departments than creative
research divisions and to develop an endless array of “me
too” products.2
I referred to France because Prescrire is one of the very
few journals where none of the editors or authors are
allowed to have conflicts of interest in relation to the drug
industry.2 The French results have global value, as the drug
market is global, and I believe it is clear that I have tried to
address the global problems we are facing with develop-
ment, pricing and usage of drugs and not only those in
high-income countries. Since 1981, Prescrire’s Pilule d’Or
(Golden Pill) has been granted to drugs that constitute a
major therapeutic advance in a field in which no treatment
was previously available. There was no worthy candidate
for 1982, 1984, 1985, 1990, 1991, from 1993 to 1995, for
1997, from 1999 to 2005, from 2008 to 2013, and for
2015.3
The statement by Raj that novel drugs for infectious dis-
eases come second after cancer drugs among new FDA
approvals is not reassuring. Everywhere, people complain
about antibiotic resistance and the lack of innovative antibi-
otics,4,5 and no matter how many “novel” drugs FDA has
approved, the clinical situation has not improved during the
last 20 years. Patients die in huge numbers because we do not
have effective antibiotics against tuberculosis, methicillin-
resistant staphylococci, beta-lactamase-producing E. coli, car-
bapenemase-producing organisms and so forth. The paper Raj
refers to only says that 14% of the novel drugs were for infec-
tions, not whether these drugs were antibiotics, immunoglobu-
lins, vaccines, or something else, or whether they were simply
“me too” drugs with no added value.6 It is similarly
misleading when Raj praises progress against cancer because
extremely few cancer drugs add anything of value.7
Raj asserts that around half of the newer drugs were
approved for acute and intermediate disease conditions and
argues that this contradicts my statement that the industry
tends to focus on drugs to treat chronic conditions that
affect many people. Raj seems to have a naive view about
what the drug industry does and why. Illegal marketing is
one of the most common and profitable crimes the drug
industry commits,2 and many drugs that should only have
been used short-term end up being used for life, for exam-
ple psychiatric drugs, although the long-term use of these
drugs causes vastly more harm than good.8,9
Raj believes I underestimate the importance of adaptive
trial designs. These designs allow drugs to be approved
based on observational data only, which is a disaster for
public health.10 Our drugs are already the third leading cause
of death after heart disease and cancer,2,9 and the lowering
of regulatory standards for new cancer drugs and other
drugs has increased the rate of drug withdrawals because of
safety issues2 and has undoubtedly increased the death toll
further.
Considering all the unnecessary deaths we cause with
drugs most people don’t really need,2,9 we must require
that trials submitted for obtaining marketing authorization
are large enough and have run for sufficient lengths of time
to capture rare but lethal harms and we should avoid
approving drugs based on surrogate outcomes. We do not
approve cars based on the fact that we can start the engine.
We require more than this, in particular safety studies. But
with drugs, which kill about 10 times more people in my
country than cars do, we do not care that we have not
requested adequate safety data.2 This is insane.
Raj argues for a holistic approach where nondrug
and drug therapies complement each other rather than con-
sidering them as mutually exclusive components. Fine, but
first we must stop the lethal drug epidemic, which means
using drugs far less than we do today. Whenever we can,
we should prefer nondrug therapies, as they don’t kill
people.[The copyright line for this article was changed on 25 July 2018 after
original online publication.]
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Raj misquotes me when he asserts that I was not the
first to envision a future without patents. Of course, I
wasn’t but in the working group I participated in, I coined
the idea of a future without patents and with public devel-
opment of drugs.1 The chair found these ideas far-fetched
and became very surprised when it turned out that 10 of
the 30 invited people were willing to join me.
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